Back to Hematology
Hematologyv2011Evidence-Based

EUTOS Score for Chronic Myelogenous Leukemia (CML)

Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.

Clinical Input Parameters

percentage
Range: 0 — 100 percentage
cm
Range: 0 — 30 cm
Clinical Assessment
Awaiting Parameters
eutos score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The EUTOS Score for Chronic Myelogenous Leukemia (CML) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

EUTOS Score = (7 × basophil percentage) + (4 × spleen size in cm)

Clinical Pearls & Practice Notes

  • Can only be applied to newly-diagnosed patients before starting therapy
  • Developed and validated in patients treated with imatinib
  • Spleen size estimation is subjective but included in validation studies
  • Outcomes may not apply to newer generation tyrosine kinase inhibitors
  • Score ≤87 indicates low risk, >87 indicates high risk

Evidence & Literature Citations

  1. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038.
  2. Hoffman R, Nagler A, Keating A, Kamel-Reid S, Lipton JH. The EUTOS score predicts outcome in CML patients treated with nilotinib front-line. Blood. 2012 Dec 6;120(23):4684; author reply 4684-5. doi: 10.1182/blood-2012-08-449249.
  3. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 update. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569.

Score Interpretation Ranges

Low Risk0 – 87 pts

Low risk for CML progression

High Risk88 – 1000 pts

High risk for CML progression

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.